Recombinant human erythropoietin treatment for chemotherapy-related anemia in children

VARAN A., BUYUKPAMUKCU M., KUTLUK T., Akyuz C.

PEDIATRICS, cilt.103, sa.2, 1999 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 103 Sayı: 2
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1542/peds.103.2.e16
  • Dergi Adı: PEDIATRICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective. The efficacy and safety of recombinant human erythropoietin (rHuEPO) treatment in chemotherapy-induced anemia in children were investigated, rHuEPO is used to treat chemotherapy-induced anemia. Several studies recommend 150 to 300 IU/kg rHuEPO for 2 to 8 months. There are only a few controlled trials in children and no precise data about the optimal dose and duration of rHuEPO treatment is available.